Indian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for its CAR-T cell therapy NexCAR19. The therapy is the first of its kind to be developed in India and will be used to treat certain types of blood cancers. ImmunoACT intends to make the drug available to partner hospitals as soon as possible.
